Endome-trial flushing of low molecular weight heparin improves decidualisation a prospective randomised control pilot study

niversity of Warwick (UK)0 个研究点目标入组 40 人开始时间: 2012年10月16日最近更新: 2016年10月17日

适应症

试验速览

暂无简介。

•1. Women attending the Centre for Reproductive Medicine, University Hospitals of Coventry and Warwickshire NHS Trust, Coventry who had previous one unsuccessful IVF treatment (defined as failure to achieve live birth after transfer of two good quality embryos)
•2. Women with recurrent miscarriages (defined as 3 or more unexplained miscarriages)
•3. Women 18 years of age or older but younger than 45 years old
•4. Able and willing to give informed consent

•1. Women who had unprotected sexual intercourse during the month when endometrial flushing is planned
•2. Women having a vaginal infection, these women will be eligible for inclusion once treatment of the infection has been completed
•3. Pregnancy
•4. Breast feeding
•5. Women with weight of < 45 kg (due to higher risk of bleeding)
•6. Women with bleeding disorders
•7. Women with severe hypertension
•8. Women with Known Renal or Liver Diseases
•9. Women who had recent stroke
•10. Women taking Warfarin for any medical condition
•11. Women taking systemic steroids, systemic salicylates, acetylsalicylic acid, NSAIDS including Ketorolac, dextran and clopidogrel or any immunosuppressant medications
•12. Women with Diabetes Mellitus (due to potential risk of hyperkalaemia)
•13. Women with hypersensitivity to Heparin, Pork, Beef or other Animal products
•14. Women with Peptic Ulcers
•15. Women undergoing Tubal Patency testing, Hysteroscopy or Laparoscopy at the time when endometrial flushing is planned

发起方

niversity of Warwick (UK)